^
    Back
    Association details:
    Biomarker:ADH1C mutation
    Cancer:Ovarian Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    cyclophosphamide (Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Pharmacogenomics
    Title:

    Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer

    Published date:
    11/09/2020
    Excerpt:
    ...104 ovarian cancer patients receiving cisplatin-cyclophosphamide chemotherapy. SNPs in TPMT and NQO1 were significantly associated with progression-free survival. A SNP in ADH1C was correlated with complete tumor response.
    DOI:
    10.2217/pgs.13.237